Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Trimetazidine

Known as: 1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride, Piperazine, 1-((2,3,4-trimethoxyphenyl)methyl)-, Trimetazidine [Chemical/Ingredient] 
A vasodilator used in angina of effort or ischemic heart disease.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Diabetes mellitus is an important and prevalent risk factor for congestive heart failure. Diabetic cardiomyopathy has been… Expand
  • figure 1
  • figure 2
Is this relevant?
Review
2010
Review
2010
Objective To explore whether trimetazidine could improve symptoms, cardiac functions and clinical outcomes in patients with heart… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Background— The anti-ischemic agent trimetazidine improves ejection fraction in heart failure that is hypothetically linked to… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
AIMS The addition of trimetazidine to standard treatment has been shown to improve left ventricular (LV) function in patients… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
OBJECTIVES This study sought to assess whether the long-term addition of trimetazidine to conventional treatment could improve… Expand
Is this relevant?
Review
2005
Review
2005
 
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND Trimetazidine (TMZ) has been shown to partially inhibit free fatty acid oxidation by shifting substrate utilization… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
AIMS To assess the antiischaemic efficacy and tolerability of the metabolic agent trimetazidine in combination with metoprolol in… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Trimetazidine is a clinically effective antianginal agent that has no negative inotropic or vasodilator properties. Although it… Expand
  • figure 2
  • figure 1
  • figure 3
  • table 1
  • figure 4
Is this relevant?
Review
1997
Review
1997
It is now clear that the availability of different metabolic substrates can have a profound influence on the extent of damage… Expand
  • figure 1
  • figure 3
  • table 1
Is this relevant?